| scholarly article | Q13442814 |
| P356 | DOI | 10.2147/OTT.S12480 |
| P953 | full work available at URL | https://europepmc.org/articles/PMC2962303 |
| https://www.dovepress.com/getfile.php?fileID=7711 | ||
| https://europepmc.org/articles/PMC2962303?pdf=render | ||
| P932 | PMC publication ID | 2962303 |
| P698 | PubMed publication ID | 21049083 |
| P5875 | ResearchGate publication ID | 270132132 |
| P2093 | author name string | Guru Sonpavde | |
| Thomas E. Hutson | |||
| C. Lance Cowey | |||
| P2860 | cites work | Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. | Q52939760 |
| Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. | Q53657205 | ||
| Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha--> hypoxia response element--> VEGF cascade differentially regulates vascular response and growth rate in tumors | Q73263334 | ||
| Tumor induction of VEGF promoter activity in stromal cells | Q77349243 | ||
| Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas | Q77364528 | ||
| Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 | Q24316075 | ||
| Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. | Q24540159 | ||
| Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor | Q27651145 | ||
| Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma | Q28247085 | ||
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 | ||
| Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial | Q29615711 | ||
| BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 | ||
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 | ||
| Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma | Q29618608 | ||
| Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism | Q33834417 | ||
| Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. | Q33880227 | ||
| Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival | Q34021957 | ||
| Cytokine therapy for metastatic renal cell carcinoma | Q34251814 | ||
| Expression of angiopoietins in renal epithelial and clear cell carcinoma cells: regulation by hypoxia and participation in angiogenesis | Q34327105 | ||
| Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial | Q34534574 | ||
| Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity | Q34580980 | ||
| Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial | Q34586436 | ||
| Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma | Q34614836 | ||
| Role of VHL gene mutation in human cancer | Q35990141 | ||
| VEGF as a key mediator of angiogenesis in cancer | Q36319024 | ||
| Hypoxia-inducible factors, hypoxia, and tumor angiogenesis | Q36433511 | ||
| Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 | Q37117085 | ||
| Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma | Q37463922 | ||
| Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. | Q39916513 | ||
| Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort | Q44130026 | ||
| In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. | Q44285254 | ||
| Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery | Q44398197 | ||
| Phase I trial of pazopanib in patients with advanced cancer. | Q45976168 | ||
| Sequential sorafenib and sunitinib for renal cell carcinoma. | Q46008845 | ||
| Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis | Q47981361 | ||
| VEGF induces hyperpermeability by a direct action on endothelial cells. | Q48014396 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | renal cell carcinoma | Q1164529 |
| P304 | page(s) | 147-155 | |
| P577 | publication date | 2010-10-05 | |
| P1433 | published in | OncoTargets and Therapy | Q7092081 |
| P1476 | title | New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib | |
| P478 | volume | 3 |
Search more.